XNAS · Healthcare · Biotechnology
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.16 | 0.06 | +137.50% | $0 | ✅ Beat | +6.13% | +11.32% | — |
| 2026-03-24 | Q4 2025 | -0.18 | -0.07 | +61.11% | $0 | ✅ Beat | +20.89% | +6.37% | +34.99% |
| 2025-11-12 |
| Q3 2025 |
| -0.33 |
| -0.71 |
| -115.15% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.36 | -0.57 | -58.33% | $0 | ❌ Miss | -0.95% | +0.72% | +3.67% |
| 2025-03-03 | Q4 2024 | -0.44 | -0.52 | -18.18% | $3,000 | ❌ Miss | -3.85% | -8.33% | -25.64% |
| 2024-08-14 | Q2 2024 | -0.46 | -0.36 | +21.74% | $43,000 | ✅ Beat | +5.38% | +34.53% | +25.11% |
| 2024-05-13 | Q1 2024 | -0.30 | -0.17 | +43.33% | $33,000 | ✅ Beat | +8.52% | +14.26% | +0.00% |
| 2024-04-01 | Q4 2023 | — | -8.02 | — | $7,000 | — | -9.53% | +2.55% | -10.07% |
Showing last 8 quarters.